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Kyleigh Grieshaber, Senior BSN Student
Pittsburg State University, Irene Ransom Bradley School of Nursing
Research Colloquium 2019
Purpose

The purpose of this review of literature was to compare
the efficacy, safety, and cost of LMWH with UFH and
make decisions about selecting the best prophylactic
therapy for PE patients.
PICOT Statement

Population: Patients effected with PE
Intervention: Prophylactic use of LMWH
Comparison: Prophylactic use of UFH
Outcome: decrease in the morbidity and mortality
of PE
• Timeline: During time of prophylaxis of PE
•
•
•
•

Interventions
• Unfractionated Heparin (UFH)
• A Standard dose of UFH consists of an IV bolus of
80U/kg followed by a continuous infusion of
18U/kg/hr.
• Low Molecular Weight Heparin (LMWH)
• There are many different compounds of LMWH, but
the most common ones used are Enoxaparin Sodium,
Dalteparin Sodium, and Tinzaparin Sodium. Below,
you can see the typical dosing for each.

• LMWH dosage is determined by weight, therefore it
can be administered in the out-patient setting
• Both LMWH and UFH require 5-7 initial days of warfarin
therapy, with a therapeutic INR goal of 2-3 and aPTT goal of
1.5-2.5x control value. Once these lab values are reached, the
patient is on P.O therapy for 3-6 months, depending on the
level of risk.
Summary
• UFH and LMWH both decrease the risk of PE with no
significant difference in prophylaxis
• LMWH decreases the risk of major hemorrhage by 52%
compared to UFH.
• Shorter hospital stays are associated with the use of LMWH
because home therapy is an option
• The overall cost of LMWH is less than UFH that could
potentially save the U.S. $250 million a year.
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Conclusion
Background

• Pulmonary Embolism (PE) is the third
leading cause of cardiovascular death in the
United States with at least 950,000 deaths
annually.
• PE is the most preventable cause of
unexpected deaths in hospitalized patients,
however, it is the most common.
• 50-80% of these cases are asymptomatic,
with 70% of these cases going undetected
until it’s too late.
• Virchow’s Triad identifies the three major
underlying factors that contribute to PE
• Stasis (changes in blood flow pattern)
• Injury (changes in blood vessel wall)
• Hypercoagulability (change in
consistency of blood)
• Risk Factors include:
• Signs and Symptoms
•
Redness
• Age > 50
• Swelling
• History of:
• Rash
• Hypotension
• Varicose veins
• Dyspnea
• Myocardial Infarction • Tachycardia
• Chest
• Cancer
discomfort
• Atrial fibrillation
• Hypoxemia
• Ischemic stroke
• Respiratory
arrest
• Diabetes mellitus
• death

• Overall, the use of LMWH is proven to be more
beneficial than the use of UFH in PE prophylaxis.
• There are several advantages including a decrease in the
risk of heparin induced thrombocytopenia and hospital
length of stay.
• Because LMWH is an effective home therapy due to its
consistent effects, it eliminates the need for intense lab
monitoring of aPTT and INR values.
Gaps in the Literature

• Larger, more diverse sample size was needed in the
article discussing the new JFK Risk Assessment tool.
• Some studies suggested different time frames for long
term anticoagulant use, regardless of the use of UFH or
LMWH.
• Dosage recommendations for UFH and LMWH
fluctuated.
• Overall, the population size was good, validity and
reliability were tested in all research studies use in this
review of literature.
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